Enanta Pharmaceuticals (ENTA) EBIT Growth (1y) (2013 - 2026)
Powered by 
Analysis
Enanta Pharmaceuticals (ENTA) EBIT Growth (1y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 8.32% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 19.82% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 145.20% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 10.14% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 269.85% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 1,528.74% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -36.55% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 99.51% |
| 10 | Enanta Pharmaceuticals | 409.30 Mn | 219.79 Mn | - | 8.77% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 8.77% |
| Mar 31, 2026 | 51.68% |
| Dec 31, 2025 | 52.20% |
| Sep 30, 2025 | 38.41% |
| Jun 30, 2025 | 21.88% |
| Mar 31, 2025 | 25.14% |
| Dec 31, 2024 | 32.51% |
| Sep 30, 2024 | 3.79% |
| Jun 30, 2024 | 34.12% |
| Mar 31, 2024 | 16.95% |
| Dec 31, 2023 | -16.24% |
| Sep 30, 2023 | -14.72% |
| Jun 30, 2023 | -12.82% |
| Mar 31, 2023 | -16.56% |
| Dec 31, 2022 | 1.30% |
| Sep 30, 2022 | 19.80% |
| Jun 30, 2022 | 3.86% |
| Mar 31, 2022 | -13.96% |
| Dec 31, 2021 | -147.25% |
| Sep 30, 2021 | -70.48% |